While fatty liver disease is a well-characterized entity, it is currently getting a completely new image. Its treatment is
clearly an interdisciplinary challenge. The number of patients with fatty liver disease will be by no means negligible.
The issue of fatty liver disease is not infrequently referred to in association with statin therapy instituted in an effort
to treat metabolic syndrome and to reduce cardiovascular risks as part of preventive therapy. The attention focused on
the increase in alanin aminotransferase levels during statin therapy is absolutely inadequate. The study includes an
overview of the topic showing the induced rise in alanin aminotransferase is merely an accompanying phenomenon,
mostly of no clinical relevance. An acceptable increase in alanin aminotransferase should not provide a reason for statin
withdrawal in the usual spectrum of patients with metabolic syndrome and fatty liver disease. A distinct advantage
is cooperation among a hepatologist, a cardiologist, and a diabetes expert.
fatty liver disease, statin, alanin aminotransferase, cardiovascular disease.